Literature DB >> 28838357

Integrated Genomic Medicine: A Paradigm for Rare Diseases and Beyond.

N J Schork1, K Nazor2.   

Abstract

Individualized medicine, or the tailoring of therapeutic interventions to a patient's unique genetic, biochemical, physiological, exposure and behavioral profile, has been enhanced, if not enabled, by modern biomedical technologies such as high-throughput DNA sequencing platforms, induced pluripotent stem cell assays, biomarker discovery protocols, imaging modalities, and wireless monitoring devices. Despite successes in the isolated use of these technologies, however, it is arguable that their combined and integrated use in focused studies of individual patients is the best way to not only tailor interventions for those patients, but also shed light on treatment strategies for patients with similar conditions. This is particularly true for individuals with rare diseases since, by definition, they will require study without recourse to other individuals, or at least without recourse to many other individuals. Such integration and focus will require new biomedical scientific paradigms and infrastructure, including the creation of databases harboring study results, the formation of dedicated multidisciplinary research teams and new training programs. We consider the motivation and potential for such integration, point out areas in need of improvement, and argue for greater emphasis on improving patient health via technological innovations, not merely improving the technologies themselves. We also argue that the paradigm described can, in theory, be extended to the study of individuals with more common diseases.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DNA sequencing; Functional genomics; Genomics; Individualized medicine; Induced pluripotent stem cells; N-of-1 clinical trials

Mesh:

Year:  2017        PMID: 28838357      PMCID: PMC6383766          DOI: 10.1016/bs.adgen.2017.06.001

Source DB:  PubMed          Journal:  Adv Genet        ISSN: 0065-2660            Impact factor:   1.944


  148 in total

Review 1.  The role of companion diagnostics in the development and use of mutation-targeted cancer therapies.

Authors:  Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein
Journal:  Nat Biotechnol       Date:  2006-08       Impact factor: 54.908

Review 2.  Gene expression omnibus: microarray data storage, submission, retrieval, and analysis.

Authors:  Tanya Barrett; Ron Edgar
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

3.  Noninvasive hemodynamic measurements: an important advance in individualizing drug therapies for hypertensive patients.

Authors:  John M Flack
Journal:  Hypertension       Date:  2006-03-06       Impact factor: 10.190

4.  In silico analysis of SNPs and other high-throughput data.

Authors:  Neema Jamshidi; Thuy D Vo; Bernhard O Palsson
Journal:  Methods Mol Biol       Date:  2007

Review 5.  The mighty mouse: genetically engineered mouse models in cancer drug development.

Authors:  Norman E Sharpless; Ronald A Depinho
Journal:  Nat Rev Drug Discov       Date:  2006-08-18       Impact factor: 84.694

Review 6.  Use of CEPH and non-CEPH lymphoblast cell lines in pharmacogenetic studies.

Authors:  Sunita J Shukla; M Eileen Dolan
Journal:  Pharmacogenomics       Date:  2005-04       Impact factor: 2.533

Review 7.  Genomic medicine: genetic variation and its impact on the future of health care.

Authors:  Huntington F Willard; Misha Angrist; Geoffrey S Ginsburg
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-08-29       Impact factor: 6.237

Review 8.  Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers.

Authors:  Mark R Trusheim; Ernst R Berndt; Frank L Douglas
Journal:  Nat Rev Drug Discov       Date:  2007-04       Impact factor: 84.694

Review 9.  An overview on the generation of BAC transgenic mice for neuroscience research.

Authors:  X William Yang; Shiaoching Gong
Journal:  Curr Protoc Neurosci       Date:  2005-05

Review 10.  A review of structural magnetic resonance neuroimaging.

Authors:  M Symms; H R Jäger; K Schmierer; T A Yousry
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-09       Impact factor: 10.154

View more
  4 in total

1.  Artificial Intelligence and Personalized Medicine.

Authors:  Nicholas J Schork
Journal:  Cancer Treat Res       Date:  2019

2.  Power and Design Issues in Crossover-Based N-Of-1 Clinical Trials with Fixed Data Collection Periods.

Authors:  Yanpin Wang; Nicholas J Schork
Journal:  Healthcare (Basel)       Date:  2019-07-02

3.  Comparison of Metabolites and Gut Microbes between Patients with Ulcerative Colitis and Healthy Individuals for an Integrative Medicine Approach to Ulcerative Colitis-A Pilot Observational Clinical Study (STROBE Compliant).

Authors:  Cheol-Hyun Kim; Young-Ung Lee; Kwang-Ho Kim; Sunny Kang; Geon-Hui Kang; Hongmin Chu; Sangkwan Lee
Journal:  Diagnostics (Basel)       Date:  2022-08-15

Review 4.  Current Challenges of iPSC-Based Disease Modeling and Therapeutic Implications.

Authors:  Michael Xavier Doss; Agapios Sachinidis
Journal:  Cells       Date:  2019-04-30       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.